1128-90-1

Basic information

• Product Name: 3-nitro-8-selena-7,9-diazabicyclo[4.3.0]nona-2,4,6,9-tetraene
• Synonyms: 3-nitro-8-selena-7,9-diazabicyclo[4.3.0]nona-2,4,6,9-tetraene;5-NITRO-BENZO(1,2,5)SELENADIAZOLE
• CAS NO: 1128-90-1
• Molecular Formula: C6H3N3O2Se
• Molecular Weight: 228.07
• Mol File: 1128-90-1.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 356.3°Cat760mmHg
• Flash Point: 169.3°C
• Appearance: /
• Density: g/cm³
• Vapor Pressure: 6.07E-05mmHg at 25°C
• CAS DataBase Reference: 3-nitro-8-selena-7,9-diazabicyclo[4.3.0]nona-2,4,6,9-tetraene(CAS DataBase Reference)
• NIST Chemistry Reference: 3-nitro-8-selena-7,9-diazabicyclo[4.3.0]nona-2,4,6,9-tetraene(1128-90-1)
• EPA Substance Registry System: 3-nitro-8-selena-7,9-diazabicyclo[4.3.0]nona-2,4,6,9-tetraene(1128-90-1)

Safety Data

• Hazardous Substances Data: 1128-90-1(Hazardous Substances Data)

Usage

General Description

3-nitro-8-selena-7,9-diazabicyclo[4.3.0]nona-2,4,6,9-tetraene is a chemical compound with a complex and unique structure. It is a heterocyclic compound containing nitrogen, selenium, and carbon atoms arranged in a bicyclic ring system. The presence of a nitro group indicates that it contains a nitro functional group, which is an important chemical moiety with various reactivity and pharmaceutical applications. The compound has potential applications in organic synthesis, medicinal chemistry, and materials science due to its interesting structure and potential reactivity. Further research and exploration of its properties and potential applications are warranted to fully understand the capabilities and limitations of this compound.

InChI:InChI=1/C6H3N3O2Se/c10-9(11)4-1-2-5-6(3-4)8-12-7-5/h1-3H

Upstream product

• 99-56-9 4-Nitrophenylene-1,2-diamine 

Downstream Products

• 1360067-55-5 7-benzyl-8-methyl-6-phenyl-7H-[1,2,5]selenadiazolo[3,4-e]isoindole 
• 1360067-58-8 7-benzyl-6-methyl-8-phenyl-7H-[1,2,5]selenadiazolo[3,4-e]isoindole 

Relevant articles and documents

A new facet of the reaction of nitro heteroaromatic compounds with ethyl isocyanoacetate

Nitro heteroarenes react with ethyl isocyanoacetate in the presence of 1,8-diazabicyclo[5.4.0]undecene (DBU) to give pyrroles or pyrimidine N-oxide depending on the structure of the starting nitro compounds. For example, 4-nitro-2,1,3-benzothiadiazole 3a reacted with ethyl isocyanoacetate to give ethyl 2,1,3-benzothiadiazolo[3,4-c]pyrrole-2-carboxylate 4a (33%), while a similar reaction with 5-nitro-2,1,3-benzothiadiazole 3b gave the corresponding compound 4b (21%) as a sole product. A plausible mechanism for these reactions is presented.

Selenadiazole derivatives as theranostic agents for simultaneous cancer chemo-/radiotherapy by targeting thioredoxin reductase

The lack of early and timely diagnosis of tumors and the monitoring of their response to therapeutics have limited the successful cancer treatments. Theranostic agents are expected to realize the dual-purpose of simultaneous diagnosis and therapy for treatments of cancers. In the present study, we have examined the effects of the chemical structure of selenadiazole derivatives (SeDs) on their anticancer efficacy and radio-sensitization against clinically used X-rays. The results showed that the introduction of a nitro group (-NO2) into SeD-3 significantly enhanced the anticancer activity of SeDs. The higher lipophilicity endowed SeD-3 with higher cellular internalization ability, resulting in higher cellular uptake and anticancer efficacy. Specifically, the capacity of autofluorescence allowed the use of SeD-3 as a promising theranostic agent to directly monitor the cellular uptake, localization and biodistribution in vitro and in vivo. Interestingly, SeD-3 also significantly enhanced the sensitivity of HeLa cervical cells to X-ray-induced apoptosis by targeting the inhibition of TrxR and promoting intracellular ROS overproduction, which activated the downstream ROS-mediated signaling pathways to regulate cell apoptosis. Furthermore, SeD-3 exhibited satisfactory in vivo antitumor efficacy through the inhibition of tumor proliferation and induction of tumor cell apoptosis, and showed no toxicity to the main organs. Moreover, from the results of hematological analysis, we found that not only inhibiting the tumor growth, treatment of SeD-3 also alleviated the damage of liver, kidney and heart function of nude mice induced by HeLa xenografts. Taken together, this study demonstrates that SeDs could be further developed as an effective and safe theranostic agent for simultaneous cancer chemo-/radiotherapy.